Skip to main content

Advertisement

SpringerLink
Log in

Clinical characteristics and prognostic factors of colorectal cancer patients with ovarian metastasis: a multicenter retrospective study

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Purpose

As a kind of secondary tumor of the ovary, ovarian metastasis from colorectal cancer (OMCRC) happens rarely. Prognostic factors of OMCRC are still undetermined. This study was conducted to analyze clinical characteristics and prognostic factors of OMCRC patients.

Methods

Data of patients with OMCRC were collected retrospectively from four large-capacity hospitals in China. Kaplan-Meier method was applied to estimate disease-specific overall survival (OS), and multivariate Cox regression analysis was used to identify prognostic factors. A novel nomogram was developed to estimate individual survival probability, whose performance was internally validated using concordance index (C-index) and calibration curve.

Results

Totally, 162 cases were eligible, with a median age at diagnosis of 49 years old. The median size of ovarian metastases was 9.0 cm (95% CI: 8.5–10.4 cm). 93.8% of patients received surgery of ovarian metastases. Median time from CRC diagnosis to metachronous ovarian metastasis was 13.0 months (95% CI: 13.5–17.7 months). Median OS after ovarian metastasis diagnosis was 26.0 months (95% CI: 22.3–29.7 months). Integrating univariate and multivariate analyses, eight factors (including age, menopausal status, primary tumor location, N stage of primary tumor, surgery of primary tumor, differentiation grade, bilateral metastasis, and systemic chemotherapy) were used to develop a novel nomogram, with a C-index of 0.65 (95% CI: 0.595–0.705). Calibration curves indicated relatively good agreement between predicted and actual survival.

Conclusions

This nomogram could be a promising tool to help clinicians to estimate individual survival outcome of patients with OMCRC. Further study is warranted to validate the practicality of this model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The data supporting the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    PubMed  Google Scholar 

  2. Hanna NN, Cohen AM (2004) Ovarian neoplasms in patients with colorectal cancer: understanding the role of prophylactic oophorectomy. Clin Colorectal Cancer 3(4):215–222

    Article  Google Scholar 

  3. Mata JM, Inaraja L, Rams A, Andreu J, Donoso L, Marcuello G (1988) CT findings in metastatic ovarian tumors from gastrointestinal tract neoplasms (Krukenberg tumors). Gastrointest Radiol 13(3):242–246

    Article  CAS  Google Scholar 

  4. Choi HJ, Lee JH, Seo SS, Lee S, Kim SK, Kim JY, Lee JS, Park SY, Kim YH (2005) Computed tomography findings of ovarian metastases from colon cancer: comparison with primary malignant ovarian tumors. J Comput Assist Tomogr 29(1):69–73

    Article  Google Scholar 

  5. Dionigi A, Facco C, Tibiletti MG, Bernasconi B, Riva C, Capella C (2000) Ovarian metastases from colorectal carcinoma. Clinicopathologic profile, immunophenotype, and karyotype analysis. Am J Clin Pathol 114(1):111–122

    Article  CAS  Google Scholar 

  6. Ates Ozdemir D, Usubutun A (2016) PAX2, PAX8 and CDX2 expression in metastatic mucinous, primary ovarian mucinous and seromucinous tumors and review of the literature. Pathol Oncol Res 22(3):593–599

    Article  CAS  Google Scholar 

  7. Goere D, Daveau C, Elias D et al (2008) The differential response to chemotherapy of ovarian metastases from colorectal carcinoma. Eur J Surg Oncol 34(12):1335–1339

    Article  CAS  Google Scholar 

  8. Lee SJ, Lee J, Lim HY, Kang WK, Choi CH, Lee JW, Kim TJ, Kim BG, Bae DS, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS (2010) Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis. Cancer Chemother Pharmacol 66(2):229–235

    Article  Google Scholar 

  9. Sekine K, Hamaguchi T, Shoji H, Takashima A, Honma Y, Iwasa S, Kato K, Takahashi K, Kato T, Kanemitsu Y, Boku N (2018) Retrospective analyses of systemic chemotherapy and cytoreductive surgery for patients with ovarian metastases from colorectal cancer: a single-center experience. Oncology. 95(4):220–228

    Article  CAS  Google Scholar 

  10. Fujiwara A, Noura S, Ohue M, Shingai T, Yamada T, Miyashiro I, Ohigashi H, Yano M, Ishikawa O, Kamiura S, Tomita Y (2010) Significance of the resection of ovarian metastasis from colorectal cancers. J Surg Oncol 102(6):582–587

    Article  Google Scholar 

  11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5(6):649–655

    Article  CAS  Google Scholar 

  12. Crobach S, Ruano D, van Eijk R, Schrumpf M, PALGA group, Fleuren G, van Wezel T, Morreau H (2016) Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: identification of driver and passenger mutations. J Pathol Clin Res 2(3):166–174

    Article  CAS  Google Scholar 

  13. Ganesh K, Shah RH, Vakiani E, Nash GM, Skottowe HP, Yaeger R, Cercek A, Lincoln A, Tran C, Segal NH, Reidy DL, Varghese A, Epstein AS, Sonoda Y, Chi D, Guillem J, Temple L, Paty P, Hechtman J, Shia J, Weiser M, Aguilar JG, Kemeny N, Berger MF, Saltz L, Stadler ZK (2017) Clinical and genetic determinants of ovarian metastases from colorectal cancer. Cancer. 123(7):1134–1143

    Article  CAS  Google Scholar 

  14. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C (2012) Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer 11(3):191–194

    Article  Google Scholar 

  15. Huang PP, Weber TK, Mendonza C, Rodriguez-Bigas MA, Petrelli NJ (1998) Long-term survival in patients with ovarian metastases from colorectal carcinoma. Ann Surg Oncol 5(8):695–698

    Article  CAS  Google Scholar 

  16. Rayson D, Bouttell E, Whiston F, Stitt L (2000) Outcome after ovarian/adnexal metastasectomy in metastatic colorectal carcinoma. J Surg Oncol 75(3):186–192

    Article  CAS  Google Scholar 

  17. Li X, Huang H, Ran L, Fang C, Yu Y, Luo M, Qiu M (2020) Impact of ovarian metastatectomy on survival outcome of colorectal cancer patients with ovarian metastasis: a retrospective study. Cancer Manag Res 12:4493–4501

    Article  Google Scholar 

  18. Zhou R, Liu Y, Wang Y, Huo X, Zhu J, Zhang T (2020) Clinicopathological characteristics and prognosis analysis of ovarian metastases in colorectal cancer: a single-center experience. Int J Clin Oncol 25:1822–1829

    Article  CAS  Google Scholar 

  19. Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, Zhang L, van Loon K (2020) Clinicopathologic characteristics and impact of oophorectomy for ovarian metastases from colorectal cancer. Oncologist. 25(7):564–571

    Article  Google Scholar 

  20. Jiang R, Tang J, Cheng X, Zang RY (2009) Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors. Eur J Surg Oncol 35(1):92–97

    Article  CAS  Google Scholar 

  21. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G, Gruppo Oncologico Nord Ovest (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25(13):1670–1676

    Article  CAS  Google Scholar 

  22. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371(17):1609–1618

    Article  Google Scholar 

  23. Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A, GONO Foundation Investigators (2020) Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21(4):497–507

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Xiaofen Li and Wei Zhang contributed equally to this work.

Authors and Affiliations

  1. Department of Abdominal Oncology, West China Hospital of Medicine, Sichuan University, No.37 Guo Xue Xiang, Chengdu, 610041, Sichuan, People’s Republic of China

    Xiaofen Li & Meng Qiu

  2. Department of Colorectal Surgery, Changhai Hospital, Naval Medical University, Shanghai, China

    Wei Zhang & Peng Liu

  3. Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China

    Peirong Ding & Zhigang Hong

  4. Department of colorectal surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Shenyang, 110042, Liaoning, People’s Republic of China

    Rui Guo & Rui Zhang

  5. Department of Gastrointestinal Surgery, West China Hospital of Medicine, Sichuan University, Chengdu, China

    Ziqiang Wang, Yongyang Yu, Chao Fang & Wenjian Meng

Authors
  1. Xiaofen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peirong Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rui Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhigang Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ziqiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yongyang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chao Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wenjian Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Rui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Meng Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, Q.M. and Z.R.; methodology, L.X., Z.W., D.P., and G.R.; formal analysis, L.X., Z.W., and H.Z.; investigation, L.X., L.P., and W.Z.; resources, W.Z., Y.Y., F.C., M.W., and D.L.; writing (original draft preparation), L.X. and Z.W.; and writing (review and editing), D.P., Q.M., and Z.R.

Corresponding authors

Correspondence to Rui Zhang or Meng Qiu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

This study was approved by the West China Hospital, Sichuan University Ethics Committee for Clinical Investigation.

Consent to participate

Due to the retrospective nature of the study, informed consent to participate was waived.

Consent for publication

Due to the retrospective nature of the study, informed consent for publication was waived.

Code availability

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, X., Zhang, W., Ding, P. et al. Clinical characteristics and prognostic factors of colorectal cancer patients with ovarian metastasis: a multicenter retrospective study. Int J Colorectal Dis 36, 1201–1208 (2021). https://doi.org/10.1007/s00384-021-03842-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-021-03842-9

Keywords

Search

Navigation